Cancer Research Technology
Log in Register
Menu
Search
Recombinant Antibodies

Anti-PCNA, Recombinant [PC10]

Invented by David Lane from Karolinska Institutet
Invented at Cancer Research UK London Research Institute: Clare Hall Laboratories
  • Datasheet
  • Inventor Info
Print

Info

Catalogue Number 152584
Applications FACS IHC IF IP WB
Antigen/Gene or Protein Targets Proliferating cell nuclear antigen, (PCNA), also known as cyclin or polymerase delta accessory protein
Reactivity Human, Insect and Saccharomyces
Relevance Monoclonal antibody which binds a widely conserved proliferating cell nuclear antigen, present in all proliferating cells as a marker of DNA synthesis, with neoplastic diagnostic and prognostic value.

Background and Research Application
PCNA, also known as polymerase delta auxiliary protein, is essential for DNA replication and is involved in DNA excision and mismatch repair pathways. PCNA is required for cellular DNA synthesis, and in vitro replication of SV40 DNA. It helps to co-ordinate the leading and lagging strand synthesis at the replication fork. PCNA binds to the CDK inhibitor p21, the structure-specific endonucleases Fen1 and XPG, and DNA cytosine 5-methyltransferase (MCMT). PCNA is potentially a therapeutic target in cancer therapy and a useful marker for identifying the proliferation status of tumour tissue (i.e. relevant to prognosis). This antibody can be used to grade different neoplasms, e.g. astrocytoma. It can be of diagnostic and prognostic value.
This antibody was first published in 1990 when various monoclonal antibodies for PCNA were created to characterise and understand the function of this protein within cellular DNA synthesis and proliferation.
Host Mouse
Immunogen Protein A-PCNA fusion obtained from pC2T.
Subclass IgG2a
Formulation PBS only
Concentration 1mg/ml
Molecular Weight (kDa) 36
Research Area Cancer, Cell Cycle, Cell Type or Organelle Marker, Epigenetics & Nuclear Signalling
Immunogen UniProt ID P12004
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
PCNA can be used as a marker for DNA synthesis and is widely conserved between species. Anti-PCNA can detect the varying levels of PCNA within cell cycle progression and DNA synthesis, through PCNA immunoprecipitation. It is capable of staining proliferating tumour tissue, beneficial for cancer research to investigate cell cycle progression, DNA replication and rates of proliferation. This antibody can recognise epitopes conserved from man to fission yeast, given PCNA amino acid sequences share homology and the gene is present in mammals and plant cells, within a similar gene being present in the baculovirus Autographa californica.

Recommended for use on formalin-fixed paraffin embedded sections. NEUTRAL ELUTE ONLY.

Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Concentration
1mg/ml as standard

References

There are 3 reference entries for this reagent.

View All References

References: 3 entries

Zhang et al. 2018. Dev Cell. 46(4):397-409.e5. PMID: 30130530.

View  

Original hybridoma first published in Waseem et al. 1990. J Cell Sci. 96 ( Pt 1):121-9. PMID: 1695635.

View  

Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.

Europe PMC ID: 1695635

View  

Add a reference

References: 3 entries

Zhang et al. 2018. Dev Cell. 46(4):397-409.e5. PMID: 30130530.

View  

Original hybridoma first published in Waseem et al. 1990. J Cell Sci. 96 ( Pt 1):121-9. PMID: 1695635.

View  

Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.

View  

Add a reference

Inventor Information